Fig. 2.

Proportion of patients experiencing A) clinically meaningful (≥5-point) reduction in HIT-6 and B) clinically meaningful reductions in MIDAS scores during 12 weeks of treatment. HIT-6, 6-item Headache Impact Test; MIDAS, Migraine Disability Assessment. MIDAS: severe baseline disability = baseline MIDAS score, > 20; moderate baseline disability = baseline MIDAS score, 11–20; clinically meaningful reduction in MIDAS score = ≥30% reduction for severe disability and ≥ 5-point reduction for moderate disability. n values shown are the number of patients with data available for analysis of change in HIT-6 or MIDAS scores at the end of treatment. ^aP < 0.0001 versus placebo. ^bP = 0.0006 versus placebo. ^cP = 0.0093 versus placebo. ^dP = 0.0137 versus placebo